Zelira Therapeutics shares have surged more than 25 per cent after a clinical trial showed its medical marijuana drug candidate successfully treated chronic insomnia.
Zelira Therapeutics shares have surged more than 25 per cent after a clinical trial showed its medical marijuana drug candidate successfully treated chronic insomnia.